Nuveen LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY

Nuveen LLC acquired a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 154,456 shares of the company’s stock, valued at approximately $1,943,000. Nuveen LLC owned about 0.16% of ARS Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Bernard Wealth Management Corp. acquired a new position in ARS Pharmaceuticals in the fourth quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of ARS Pharmaceuticals during the first quarter worth $37,000. PNC Financial Services Group Inc. increased its holdings in ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after purchasing an additional 3,905 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in ARS Pharmaceuticals in the fourth quarter valued at about $75,000. Finally, Ball & Co Wealth Management Inc. acquired a new position in ARS Pharmaceuticals in the fourth quarter valued at about $105,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $31.00.

Insider Buying and Selling

In other news, insider Eric Karas sold 15,000 shares of the business’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $16.99, for a total value of $254,850.00. Following the sale, the insider owned 10,315 shares of the company’s stock, valued at $175,251.85. The trade was a 59.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard E. Lowenthal sold 50,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $14.49, for a total transaction of $724,500.00. Following the completion of the sale, the chief executive officer owned 1,196,494 shares in the company, valued at $17,337,198.06. The trade was a 4.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 882,649 shares of company stock valued at $15,773,760 over the last ninety days. Insiders own 33.50% of the company’s stock.

ARS Pharmaceuticals Trading Down 9.6%

SPRY opened at $11.62 on Friday. The stock has a market capitalization of $1.15 billion, a P/E ratio of -23.71 and a beta of 0.90. The company has a current ratio of 6.17, a quick ratio of 5.98 and a debt-to-equity ratio of 0.37. ARS Pharmaceuticals, Inc. has a 12 month low of $10.00 and a 12 month high of $18.90. The firm’s fifty day simple moving average is $16.55 and its 200 day simple moving average is $14.38.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.05). The firm had revenue of $15.72 million during the quarter, compared to analyst estimates of $12.92 million. ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. As a group, research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.